Pan Yimin, Liu Zhichen, Wu Changwu
Department of Neurosurgery, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China.
Department of Orthopedics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, China.
Biomedicines. 2025 Feb 25;13(3):571. doi: 10.3390/biomedicines13030571.
Recent studies have identified solute carrier family 19 member 1 (SLC19A1) as a second messenger transporter that regulates massive immune-related signaling cascades, but current studies provide limited information. This study aims to evaluate its role and the potential mechanisms across various cancers. We analyzed multi-omics data from a pan-cancer cohort to evaluate SLC19A1 expression and its association with multiple features, including prognosis, tumor stemness, genome instability, and immune infiltration. Immunofluorescence staining was performed to validate SLC19A1 expression in tumor tissues and its relationship M2 macrophages. In addition, we used web tools such as ROCplotter to evaluate the association between SLC19A1 and response to chemotherapy and immunotherapy. SLC19A1 was found to be overexpressed in multiple cancer types compared to normal tissues, correlating with poor prognosis. High SLC19A1 levels were associated with increased genomic instability and immune suppression. In addition, SLC19A1 was negatively correlated with CD8+ T-cell infiltration and positively correlated with M2 macrophage infiltration. The association of SLC19A1 with M2 macrophages was confirmed in multiple immunofluorescence staining. Finally, SLC19A1 was associated with the response to chemotherapy and immunotherapy in a variety of tumors. Our findings position SLC19A1 as a novel unfavorable prognostic marker in cancer, closely linked to immune suppression and genomic instability. This study highlights the need for further exploration of SLC19A1 as a therapeutic target and its implications in cancer treatment strategies.
最近的研究已将溶质载体家族19成员1（SLC19A1）确定为一种调节大量免疫相关信号级联反应的第二信使转运体，但目前的研究提供的信息有限。本研究旨在评估其在各种癌症中的作用及潜在机制。我们分析了来自泛癌队列的多组学数据，以评估SLC19A1的表达及其与多种特征的关联，包括预后、肿瘤干性、基因组不稳定性和免疫浸润。进行免疫荧光染色以验证SLC19A1在肿瘤组织中的表达及其与M2巨噬细胞的关系。此外，我们使用ROCplotter等网络工具来评估SLC19A1与化疗和免疫治疗反应之间的关联。结果发现，与正常组织相比，SLC19A1在多种癌症类型中均有过表达，且与预后不良相关。高SLC19A1水平与基因组不稳定性增加和免疫抑制有关。此外，SLC19A1与CD8 + T细胞浸润呈负相关，与M2巨噬细胞浸润呈正相关。通过多次免疫荧光染色证实了SLC19A1与M2巨噬细胞的关联。最后，SLC19A1与多种肿瘤的化疗和免疫治疗反应相关。我们的研究结果表明，SLC19A1是一种新的癌症不良预后标志物，与免疫抑制和基因组不稳定性密切相关。本研究强调了进一步探索将SLC19A1作为治疗靶点及其在癌症治疗策略中的意义的必要性。
